Clinical trials: Invasive Carcinoma
Breast Cancer, Invasive Breast Carcinoma
Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
This clinical trial studies the feasibility of implementing various adaptive training exercise programs to improve cardiorespiratory fitness in patients after receiving breast cancer treatment.
- Trial name
- ACTIVATE (NCT04667481)
- Testing
- Aerobic Exercise Intervention, Resistance Exercise Intervention, Exercise Intervention: Digital copies and outline of sessions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Non-small Cell Lung Cancer
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
The study is being done to determine if non-invasive testing (urine and plasma testing) is as effective as tissue testing in identifying epidermal growth factor receptor (EGFR) T790M mutation status.
- Trial name
- RADIANCE (NCT03137264)
- Testing
- Other
- Where
- 23 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Bladder Cancer
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate the efficacy and safety in patients with non-muscle invasive bladder cancer histologically diagnosed to be stage Ta and G1 or G2 and who were randomized into either an EO9 or placebo group…
- Trial name
- NCT01475266
- Testing
- EO9 (Apaziquone)
- Where
- 20 sites in Japan, South Korea
- Volunteers
- 51 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Carcinoma, Hepatocellular, Liver Neoplasms
Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis
The purpose of this study is to determine if the, MR guided, laser interstitial thermal therapy (LITT) treatment technique can be safety and efficiently used for the human liver metastasis
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms
- Trial name
- NCT00392366
- Testing
- MR-guided Laser Interstitial Thermal Therapy System
- Where
- France
- Volunteers
- 25 people
- Sponsor
- BioTex, Inc.
Invasive Ductal Breast Carcinoma
Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer
The present investigation aims to evaluate the efficacy of an innovative protocol of controlled ovarian stimulation for breast cancer patients, who are candidates for fertility preservation.
- Trial name
- DEGASTIM (NCT03947151)
- Testing
- Degarelix injection(s)
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma
Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. The objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants…
- Trial name
- HACAMI (NCT02791750)
- Testing
- questionnary of quality of life
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut de Cancérologie de Lorraine
Esophageal Cancer
Robotic Versus Thoracolaparoscopic Esophagectomy for Esophageal Cancer
Esophageal cancer is a debilitating condition. The treatment involved is complex requiring a combination of chemotherapy and surgery in most cases.
- Trial name
- NCT03727126
- Testing
- Robotic esophagectomy, Thoracolaparoscopic esophagectomy
- Where
- 2 sites in India
- Volunteers
- 40 people
- Sponsor
- GEM Hospital & Research Center
Non-muscle Invasive Bladder Cancer
The Role of Universal Cancer Only Marker SIX6 in Diagnosing Non-Muscle Invasive Bladder Cancer
Transurethral resection of bladder tumor (TURBT) is the standard therapeutic approach for patients with non-muscle-invasive bladder cancer (NMIBC).
- Trial name
- NMIBC (NCT07252297)
- Testing
- SIX6 Gene Methylation Assay
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Xijing Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
This early phase I trial tests whether letrozole with simvastatin works better than letrozole alone to stop tumor cell proliferation in patients with stage I-III hormone receptor positive, HER2 negative invasive breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
- Trial name
- NCT05464810
- Testing
- Letrozole, Simvastatin
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer.
- Conditions
- Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT01245712
- Testing
- Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial.
- Conditions
- Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade
- Trial name
- POLO (NCT06227065)
- Testing
- Epirubicin, Mitomycin, Gemcitabine
- Where
- 2 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Hospital Centre Biel/Bienne
Non Muscle Invasive Bladder Cancer
Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT
This is a prospective, open-label, single-center, single-arm phase II clinical study to evaluate the efficacy and safety of toripalimab combined with intravesical gemcitabine as adjuvant therapy in patients with high-risk…
- Trial name
- NCT07808216
- Testing
- Toripalimab (JS001 ), Gemcitabine (GEM)
- Volunteers
- 54 people
- Sponsor
- Tianjin First Central Hospital
Bladder Cancer, Kidney Tumor
Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
This pilot clinical trial studies imaging during surgery in diagnosing patients with prostate, bladder, or kidney cancer. New diagnostic imaging procedures, may find prostate, bladder, or kidney cancer
- Conditions
- Bladder Cancer, Kidney Tumor, Prostate Cancer
- Trial name
- NCT01688414
- Testing
- photoacoustic imaging, fluorescence imaging, robot-assisted laparoscopic surgery
- Sponsor
- Stanford University
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
This phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04457596
- Testing
- Trastuzumab Emtansine, Tucatinib, Questionnaire Administration
- Where
- 1,176 sites in United States, Canada and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder Cancer
A Study for Treatment of Superficial Bladder Cancer Using OGX-427
This is a single centre, open label, phase I dose escalation trial using a modified accelerated titration design. Patients with superficial bladder tumour (Ta or T1) or CIS and candidates for transurethral resection or muscle…
- Trial name
- NCT00959868
- Testing
- OGX-427
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Vancouver Coastal Health
Muscle-Invasive Bladder Carcinoma
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer.
- Trial name
- NCT06215976
- Testing
- Metformin Hydrochloride 500 MG
- Where
- Egypt
- Volunteers
- 78 people
- Sponsor
- Cairo University
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject.
- Trial name
- Hydeal Cyst (NCT06245603)
- Testing
- Hydeal Cyst®
- Where
- 9 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation.
- Conditions
- Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy
- Trial name
- NCT01643460
- Testing
- 98% Ethanol & Paclitaxel injection
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Urothelial Carcinoma Bladder, Bladder Cancer
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-naïve patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- GEMDOCE (NCT04386746)
- Testing
- Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II
Addressing Barriers to Palliative Care Use in Bladder Cancer
Investigators plan to establish an in-depth understanding of knowledge and beliefs about palliative care in advanced Bladder Cancer patients and their caregivers, and to identify factors associated with positive and negative…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II, Bladder Cancer Stage III, Bladder Cancer Stage IV
- Trial name
- NCT04598724
- Testing
- Surveys
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.